Clinical trial · Observational
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (Nat-Geno)
NCT06960798CI-TRIAL-00123830recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prostate cancer. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of your cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bio-specimen Collection | Other | — | UNRESOLVED |
| Blood Draw | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Native American Group
- description
- 150 patients will be assigned in this group.
- interventionNames
- Other: Bio-specimen Collection
- Other: Blood Draw
Primary outcomes (1)
- measure
- Difference in the genomic profiles of Prostate Cancer
- timeFrame
- 1-3 years
- description
- Comprehensively characterize the genomic profile of prostate cancer in Native American patients compared to Caucasian patients. Genetic testing will be conducted using Caris Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS).
Secondary outcomes (1)
- measure
- Comparison of Genomic Profiles
- timeFrame
- 1-3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses. * At least 18 years-of-age at the time of signature of the informed consent form (ICF). * Patients who self-identify as Native American. * Patients with a pathologically proven diagnosis of PC (any stage). * Availability of most recent archived tumor samples. Exclusion Criteria: * Patients not of Native American descent or identity. * Patient does not have archival tissue available.
References
Publications (0)
Data not yet available
No reference posted for this study.